98%
921
2 minutes
20
Background: Underlying causes of vaccine hesitancy could significantly affect successful uptake of the SARS-CoV2 vaccine booster doses during new waves of COVID-19. Booster rates among US adults are far below what is needed for immunity, but little is known about booster hesitancy among fully vaccinated adults and whether medical mistrust exacerbates barriers to uptake.
Methods: A cross-sectional survey was completed among 119 adults in Philadelphia, PA who reported having received the primary SARS-CoV2 vaccine series but not a booster dose. Using the LaVeist Medical Mistrust (MM) Index, a k-means cluster analysis showed two clusters (Low MM, High MM) and differences in attitudes and perceptions about COVID-19 booster vaccines were assessed using F-tests.
Results: Respondents were 62% Black and female; mean age was 41; 46% reported earning less than $25,000 and 53% had a high school education or less. Overall intention to get boosted was low (mean 3.3 on 0-10 scale). Differences in COVID-19 booster perceptions between those with High ( = 56) vs. Low ( = 59) MM were found, independent of any demographic differences. Most statements (7/10) related to reasons to not be boosted were significant, with those with High MM indicating more concern about feeling sick from the vaccine (F=-3.91, ≤ .001), beliefs that boosters are ineffective for vaccinated people (F= -3.46, ≤ .001), and long-term side effect worries (F=-4.34, ≤ .001). Those with High MM were also more concerned about the adverse effects of the vaccine (F=-2.48, =.02), but were more likely to trust getting information from doctors or healthcare providers (F= -2.25, =.03).
Conclusions: Results indicate that medical mistrust is an important independent construct when understanding current COVID-19 booster hesitancy. While much work has looked at demographic differences to explain vaccine hesitancy, these results suggest that further research into understanding and addressing medical mistrust could be important for implementing interventions to increase booster rates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11391872 | PMC |
http://dx.doi.org/10.1080/07853890.2024.2401122 | DOI Listing |
PLoS One
September 2025
Department of Social Science, Malawi Liverpool Wellcome Clinical Programme, Blantyre, Malawi.
Diarrhoea due to rotavirus remains a significant cause of child mortality in developing regions. Caregivers' perspectives on the social determinants of gastroenteritis and childhood vaccination, including the rotavirus vaccine, were explored through focus group discussions in Ethiopia (n = 6), Kenya (n = 14), and Malawi (n = 10), using a combination of thematic and framework analysis approaches. The results show that diarrhoea was perceived to be a burden in all three countries, particularly among infants, due to challenges in WASH (water, sanitation, and hygiene) infrastructures and poverty.
View Article and Find Full Text PDFHealth Equity
August 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Background: The participation of Black individuals in clinical trials remains lower than that of other racial and ethnic groups. Substance abuse adds additional barriers to recruitment and retention. While significant attention has been devoted to identifying barriers to recruitment/retention, efforts have been largely unsuccessful in increasing the participation of Black individuals in clinical trials.
View Article and Find Full Text PDFPatient Educ Couns
August 2025
Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Objective: To examine how communication needs regarding prognosis, treatment options, and palliative care evolve over time for patients with advanced cancer and their family caregivers, particularly as patients approach the end-of-life.
Methods: This mixed-methods study surveyed 272 patients at a California healthcare system from October 2019-November 2021 at 1, 4, 8, and 12 months after identification of advanced cancer. Additionally, 24 family caregivers were interviewed between March 2021-May 2022.
Hepatol Commun
September 2025
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Background: In Michigan, Asian Americans are disproportionately infected with HBV and HCV. As many infections are first diagnosed when patients present with advanced liver disease or liver cancer, HBV and HCV screening, awareness, and early treatment are critical to improving outcomes.
Methods: Using a theory-informed approach, we administered a bi-level qualitative study to identify determinants of viral hepatitis and liver cancer care and treatment in Michigan Asian American communities.
J Acquir Immune Defic Syndr
September 2025
Georgetown University, Department of Medicine, Division of Infectious Disease and Tropical Medicine, Washington, DC.
Background: Despite efficacy of COVID-19 vaccines in preventing severe complications of infection there remains vaccine hesitancy. We examined COVID-19 vaccine uptake and vaccine hesitancy among persons living with HIV (PWH).
Methods: A nested survey was administered to women in the District of Columbia MACS-WIHS Combined Cohort Study (10/01/2020-9/30/2022).